-
Product Insights
Sleep Apnea Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Sleep Apnea - Global Clinical Trials Review, 2025" provides an overview of Sleep Apnea Clinical trials scenario. This report provides top line data relating to the clinical trials on Sleep Apnea. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Cystic Fibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Cystic Fibrosis- Global Clinical Trials Review, 2025" provides an overview of Cystic Fibrosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Cystic Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Sector Analysis
Sleep Apnea Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Sleep Apnea Therapeutics. In 2024 and 2029, China is anticipated to have the highest number of diagnosed prevalent cases of sleep apnea, representing a large portion of global cases. Currently, the sleep apnea market is saturated with generic drugs, and the sodium-dependent dopamine transporter (DAT) drug class dominates the approved innovator drugs landscape. The sleep apnea pipeline holds 27 molecules, with one asset in the pre-registration...
-
Sector Analysis
Chronic Obstructive Pulmonary Disease (COPD) in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Chronic Obstructive Pulmonary Disease (COPD) market through 2033. GlobalData estimated that drug sales for COPD in 2023 were approximately $11.6 billion across the 7MM. The US market makes up the majority of total global sales, contributing $8.6 billion (74.1%) due to the large COPD prevalent population, combined with the high price of medication in the country. GlobalData anticipates that the COPD market will grow to...
-
Sector Analysis
Chronic Obstructive Pulmonary Disease (COPD) in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 7 major markets and provides an Excel-based forecast model for the Chronic Obstructive Pulmonary Disease (COPD) market through 2033. COPD is a progressive lung disease characterized by an abnormal inflammatory response and airflow obstruction that is not fully reversible. According to GOLD 2023, COPD has been defined as a heterogenous lung condition that is characterized by chronic symptoms (dyspnea, cough, sputum production, and/or exacerbations due to abnormalities of the airways [bronchitis, bronchiolitis] and/or alveoli [emphysema]) that...
-
Sector Analysis
Bronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, China) and provides an Excel-based forecast model for the bronchiectasis market through 2033. Report deliverables include a PowerPoint report and an Excel-based forecast model. Bronchiectasis, which has been given diagnostic code of J47.9 from the International Classification of Diseases, Tenth Edition (ICD-10), is defined by damage to the bronchi, causing abnormal dilation and scarring. The airways become inflamed with thick mucus that is difficult to clear, which build-up...
-
Product Insights
Pulmonary Fibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Pulmonary Fibrosis - Global Clinical Trials Review, 2025" provides an overview of Pulmonary Fibrosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Pulmonary Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Severe Asthma in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This new set to update and replace the previous asthma market analysis publication, Asthma: Global Drug Forecast and Market Analysis to 2029 (December 2020, GDHC208PIDR), which covered the forecast period 2019–29. This new publication covers the severe asthma market over the forecast period of 2023-33. GlobalData estimated the total severe asthma market to be valued at $5.1 billion across the 8MM, with the US accounting for 80.4% of the market. The five major European markets (5EU) (France, Germany, Italy, Spain,...
-
Product Insights
Obstructive Sleep Apnea Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Obstructive Sleep Apnea - Global Clinical Trials Review, 2024" provides an overview of Obstructive Sleep Apnea Clinical trials scenario. This report provides top line data relating to the clinical trials on Obstructive Sleep Apnea. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Asthma and Severe Asthma Epidemiology Analysis and Forecast to 2033
] Asthma and Severe Asthma Report Overview In the 8MM, there were 56,552,679 12-month diagnosed prevalent cases of asthma in 2023. The diagnosed prevalent cases will register an AGR of less than 1% during 2023-2033. Asthma is a common lung condition characterized by the narrowing and swelling of the lungs' airways and the production of excess mucus. Common asthma symptoms include wheezing, breathlessness, chest tightness, and coughing at night or early in the morning. Asthma and Severe Asthma Market Outlook,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.